Physician profile
Alison Wright
NPI 1497795090
$2,214.44
in general payments reported to CMS, 2019-2025
27 companies · $16.80 in 2025
The $16.80 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $230 · 2021: $436 · 2022: $559 · 2023: $353 · 2024: $134 · 2025: $16.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $419 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.08 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $886.33 | 2019-2023 | Liletta |
| Myovant Sciences INC. | $191.05 | 2021-2022 | |
| Astellas Pharma US INC | $174.36 | 2023-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $108.26 | 2019-2024 | Aptima, Myosure Tissue Removal Device, Novasure |
| Aspira Women'S Health INC | $92.14 | 2022 | |
| Exeltis, USA INC. | $64.49 | 2020-2023 | Slynd |
| Roche Diagnostics Corporation | $62.80 | 2019-2020 | |
| Caldera Medical, INC | $57.12 | 2021 | |
| Therapeuticsmd, INC. | $56.89 | 2020-2022 | |
| Pfizer INC. | $55.15 | 2019-2024 | |
| Baxter Healthcare | $49.18 | 2023-2024 | Floseal, Perclot |
| Biom'Up France Sas | $46.71 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.43 | 2019 | |
| Mylan Pharmaceuticals INC. | $41.31 | 2020-2021 | |
| Organon LLC | $39.82 | 2022-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $36.14 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $25.39 | 2019-2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Biohaven Pharmaceuticals, INC. | $24.22 | 2021 | |
| Shield Therapeutics INC | $23.51 | 2023 | Accrufer |
| Olympus America INC. | $21.57 | 2019 | |
| Sumitomo Pharma America, INC. | $20.97 | 2024 | Myfembree |
| Biohaven Pharmaceutical Holding Company LTD. | $19.69 | 2022 | |
| Mayne Pharma Commercial LLC | $19.49 | 2021 | |
| Amag Pharmaceuticals, INC. | $16.45 | 2019 | |
| Agile Therapeutics, INC. | $14.14 | 2021 | |
| Minerva Surgical, INC | $10.85 | 2019 | |
| Meditrina | $9.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.